The latent HIV reservoir is a major barrier to HIV cure. Despite advancements in keeping viral loads below detectable limits, HIV-1 still exists within a latent reservoir in vivo and viral replication returns when anti-retroviral therapy (ART) is interrupted.
Nancie M. Archin, PhD, and Edward P. Browne, PhD, sought to improve HIV reactivation with a synergistic latency reversal agent combination AZD5582 & I-BET151 using an CRISPR screening approach.